UNSPSC 51271502: Ethyl chloride

This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46U771ERWK. European Medicines Agency schedules Ethyl chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13740MIG. Ethyl chloride generally arises in the molecular formula C2H5CL. The term ETHYL CHLORIDE is a U.S. Pharmacopeial Convention designation. Most nations schedule ethyl chloride under HS 29031190 and SITC 51136.

As of Q4 2014, ETHYL CHLORIDE remains the US FDA Preferred Term for this commodity. Ethyl chloride bears US NLM identifiers UMLS ID C0015058 and NCI Concept Code C75067. SMILES: CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])CL)CL.[NA+].

UNSPSC 51271502 Ethyl chloride, a Commodity code, covers pharmaceutical and chemical agents used in state and local healthcare and medical supply operations. State and local governments procure ethyl chloride primarily as a topical anesthetic and cooling agent for clinical settings—emergency departments, urgent care facilities, and medical offices administered by state health departments, county health authorities, and municipal healthcare systems. Recent activity shows state and local purchasing focused on establishing framework agreements with manufacturers and wholesalers to ensure consistent availability and competitive pricing across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with responses due March 26, 2026. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements. Evaluation prioritizes price competitiveness (75 percent) alongside compliance with administrative data formats, EDI capability, and contractual relationships with at least two of the three authorized wholesalers; vendors must carry commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000. The contract term runs two years for new responders with optional MMCAP extensions, with awarded agreements effective July 1, 2026 and participating states including Minnesota and Oregon. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with all products required to be available in the marketplace by May 15, 2026.